Novel end points for clinical trials in young children with cystic fibrosis
MetadataShow full item record
Cystic fibrosis (CF) lung disease commences early in the disease progression and is the most common cause of mortality. While new CF disease-modifying agents are currently undergoing clinical trial evaluation, the implementation of such trials in young children is limited by the lack of age-appropriate clinical trial end points. Advances in infant and preschool lung function testing, imaging of the chest and the development of biochemical biomarkers have led to increased possibility of quantifying mild lung disease in young children with CF and objectively monitoring disease progression over the course of an intervention. Despite this, further standardization and development of these techniques is required to provide robust objective measures for clinical trials in this age group.
Showing items related by title, author, creator and subject.
An integrated approach to outcome evaluation : incorporating patient reported outcomes in heart failureChang, Sungwon (2012)Globally individuals and health care systems are facing the burden of chronic illness. The impact of the increasing burden of non-communicable diseases is experienced by individuals and health care systems. Across the ...
Impact of a Telenursing service on satisfaction and health outcomes of children with inflammatory rheumatic diseases and their families: A crossover randomized trial study protocolRamelet, Anne-Sylvie; Fonjallaz, B.; Rapin, J.; Gueniat, C.; Hofer, M. (2014)Background: Pediatric rheumatic diseases have a significant impact on children's quality of life and family functioning. Disease control and management of the symptoms are important to minimize disability and pain. ...
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trialMartin, M.; Holmes, F.; Ejlertsen, B.; Delaloge, S.; Moy, B.; Iwata, H.; von Minckwitz, G.; Chia, S.; Mansi, J.; Barrios, C.; Gnant, M.; Tomaševic, Z.; Denduluri, N.; Šeparovic, R.; Gokmen, E.; Bashford, A.; Ruiz Borrego, M.; Kim, S.; Jakobsen, E.; Ciceniene, A.; Inoue, K.; Overkamp, F.; Heijns, J.; Armstrong, A.; Link, J.; Joy, A.; Bryce, R.; Wong, A.; Moran, S.; Yao, B.; Xu, F.; Auerbach, A.; Buyse, M.; Chan, Arlene; ExteNET Study Group (2017)Background: ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after trastuzumab-based adjuvant therapy in women with ...